Sector News

Inositec names ex-Roche, Novartis staffer as CMO

January 19, 2018
Life sciences

Inositec has named former Roche and Novartis staffer Frits van Alphen, M.D., as its CMO. Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.

Zurich, Switzerland-based Inositec hired van Alphen away from Roche, where he led the operational excellence team. Earlier in his career, van Alphen worked as CMO of Vifor Pharma and headed up European medical affairs at Novartis. The Novartis role also gave van Alphen responsibility for leading the company’s clinical operations team in the Netherlands. Van Alphen will now use this experience to guide Inositec into and through the clinic.

Inositec spun out of ETH Zurich late in 2015 to develop drugs based on inositol hexaphosphate. The biotech has a platform capable of replacing phosphate groups on the molecule with a view to giving them druglike properties. Inositec sees the small molecules treating a range of conditions. Vascular calcification is top of its hit list.

The small molecules advancing down the pipeline at Inositec are designed to inhibit pathological crystallization in soft tissues and thereby prevent the stiffening and blockage of arteries. If the R&D strategy goes according to plan, the drugs will have these effects regardless of the root cause of the vascular calcification, making them suitable for use in all calcification-dependent cardiovascular diseases.

Inositec is some way from clinically validating its belief in this mechanism. But with van Alphen in the CMO seat, it has taken another step toward generating supportive data.

“Dr. van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with our lead program in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019,” Inositec CEO Mattias Ivarsson, Ph.D., said in a statement.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend